New Spherix Data in Alzheimer’s Disease Reveals High Potential for Emerging Anti-Amyloid Therapies from Genentech, Biogen/Eisai, and Eli Lilly, As...
Spherix’s Eric John reveals preliminary data on two new oral agents and how they are impacting the ulcerative colitis market...
232 US specialists provided feedback on their use and perceptions of biosimilar agents and their impact on the total treatment...
Will the first and only FDA-approved therapy indicated for EoE fill the treatment void expressed by gastroenterologists? EXTON, Pa., June...
The project is designed to explore to what degree the next generation of specialists are prepared to enter clinical practice...
Gastroenterologists report strong awareness, familiarity, and patient initiations for Rinvoq, relative to recent launches EXTON, Pa., June 7, 2022 /PRNewswire...
Ten NAFLD/NASH pipeline product profiles were evaluated by US gastroenterologists and hepatologists to assess strengths, weaknesses, and physician receptivity EXTON,...
The company is also the most geographically dispersed gastroenterology organization in the U.S., according to a report jointly published by...
In 2021, the number of private equity acquisitions of gastroenterology practices grew by 28% over the previous year, according to...
What do physicians think about the emerging market for recurrent C. diff? That depends on who you talk to, especially...
Roche trumpeted a “major advancement” in the retinal space with the approval of its eye drug Susvimo last October, touting...
Market entry of Ardelyx’s Ibsrela has potential to disrupt the treatment landscape EXTON, Pa., May 12, 2022 /PRNewswire/ — Spherix...
